+- Diễn đàn xét nghiệm đa khoa (https://xetnghiemdakhoa.com/diendan)
+-- Diễn đàn: ...:::THƯ VIỆN SÁCH - GIÁO TRÌNH - TÀI LIỆU:::... (https://xetnghiemdakhoa.com/diendan/forum-29.html)
+--- Diễn đàn: Tài liệu xét nghiệm (https://xetnghiemdakhoa.com/diendan/forum-31.html)
+---- Diễn đàn: Laboratory Books (https://xetnghiemdakhoa.com/diendan/forum-221.html)
+---- Chủ đề: [Ebooks] Biomarkers of Disease-An Evidence based Approach 2002 (/thread-7520.html)
Biomarkers of Disease-An Evidence based Approach 2002 - QLAB - 05-16-2021
Biomarkers of Disease-An Evidence based Approach 2002
![[Image: IiOBaX1.jpg]](https://i.imgur.com/IiOBaX1.jpg)
Biological markers or ‘biomarkers’ of organ damage and dysfunction occupy a central position in the armamentarium of the clinician that is used for the screening, diagnosis and management of disease. Our knowledge of the pathophysiological basis of individual diseases continues to increase inexorably and the discoveries emanating from the Human Genome Project are set to enhance this knowledge immeasurably. Understanding the aetiopathogenesis of changes that take place in individual tissues, organs or compartments of the body can help in the search for markers that reflect these changes. Some of these changes may be directly related to the pathological abnormality while others might be a secondary consequence of the abnormality.
Basic research into the pathophysiology of a disease provides the foundation of knowledge that can lead to the discovery of valuable biomarkers. This foundation can also act as the starting point for the discovery of pharmaceutical interventions. Increasingly, with a more systematic approach to biomarker development and drug discovery, we are seeing the measurement of the biomarker playing a greater role in monitoring the efficacy and/or side effects of the therapeutic intervention. From a clinical standpoint, this can have a major benefit in assessing compliance with therapy, which is acknowledged to be one of the key determinants of efficacy, especially when there is no other ready means to judge the patient’s response.
The discovery of a new biomarker is complemented by the development and validation of appropriate analytical technology. The appropriateness can be viewed in relation to a number of performance characteristics and the mode of delivery. Thus, the test may be delivered on an automated analytical platform from a centralized laboratory facility or by means of a point of care testing device. The ability to deliver the test at the point of care, with the immediacy of response, may be a key factor in ensuring the clinical utility of the test. The basic analytical characteristics include imprecision and inaccuracy which, together with the issues surrounding the biological variation and stability of the biomarker, constitute the core components of technical performance.
Basic research into the pathophysiology of a disease provides the foundation of knowledge that can lead to the discovery of valuable biomarkers. This foundation can also act as the starting point for the discovery of pharmaceutical interventions. Increasingly, with a more systematic approach to biomarker development and drug discovery, we are seeing the measurement of the biomarker playing a greater role in monitoring the efficacy and/or side effects of the therapeutic intervention. From a clinical standpoint, this can have a major benefit in assessing compliance with therapy, which is acknowledged to be one of the key determinants of efficacy, especially when there is no other ready means to judge the patient’s response.
The discovery of a new biomarker is complemented by the development and validation of appropriate analytical technology. The appropriateness can be viewed in relation to a number of performance characteristics and the mode of delivery. Thus, the test may be delivered on an automated analytical platform from a centralized laboratory facility or by means of a point of care testing device. The ability to deliver the test at the point of care, with the immediacy of response, may be a key factor in ensuring the clinical utility of the test. The basic analytical characteristics include imprecision and inaccuracy which, together with the issues surrounding the biological variation and stability of the biomarker, constitute the core components of technical performance.
This site comply with DMCA digital copyright. We do not store files not owned by us, or without the permission of the owner. We also do not have links that lead to sites DMCA copyright infringement.
If You feel that this book is belong to you and you want to unpublish it, Please contact admin's email: xetnghiemdakhoa@gmail.com. Thanks!